Drug intelligence / Profile preview

emibetuzumab

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Emibetuzumab is a humanized IgG4 bivalent monoclonal antibody developed by Eli Lilly for the treatment of various cancers, including non-small cell lung cancer (NSCLC), gastric cancer, renal cell carcinoma, hepatocellular carcinoma, and advanced solid tumors. It targets the hepatocyte growth factor receptor (HGFR/c-Met) and inhibits both HGF-dependent and HGF-independent MET signaling. Emibetuzumab acts by binding to the extracellular domain of MET, blocking ligand (HGF) binding and inducing internalization and downregulation of MET receptors on tumor cells. This dual mechanism results in inhibition of tumor growth driven by aberrant MET activation[1][3][4][6].

Other names: emibetuzumab

Targets

MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on emibetuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on emibetuzumab.

Explore the full profile